



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Blocklisting Six Monthly Return**

**London: Monday, 29 December 2014:** Chi-Med announces the following blocklisting six monthly return:

1. Name of applicant:	Hutchison China MediTech Limited
2. Name of scheme:	Hutchison China MediTech Limited Share Option Scheme
3. Period of return:	From 29 June 2014 to 28 December 2014
4. Balance under scheme from previous return:	876,279 ordinary shares of US\$1 each
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:	Nil
6. Number of securities issued/allotted under scheme during period:	180,228 ordinary shares of US\$1 each
7. Balance under scheme not yet issued/allotted at end of the period:	696,051 ordinary shares of US\$1 each
8. Number and class of securities originally listed and the date of admission:	2,560,606 ordinary shares of US\$1 each admitted on 26 June 2007
9. Total number of securities in issue at the end of the period:	53,076,676 ordinary shares of US\$1 each
Name of contact:	Christian Hogg
Address of contact:	21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:	+852 2121 8200

**Ends**

## Enquiries

### **Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

### **Panmure Gordon (UK) Limited**

Richard Gray

Andrew Potts

Telephone: +44 20 7886 2500

### **Citigate Dewe Rogerson**

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

## About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).